Stockscreener 앱 받기
317.25
6.55%
19.51
전일 마감가:
$297.74
열려 있는:
$299.07
하루 거래량:
563.22K
Relative Volume:
0.54
시가총액:
$8.80B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-34.60
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+9.98%
1개월 성능:
+15.57%
6개월 성능:
+491.55%
1년 성능:
+351.60%
1일 변동 폭
$295.47
$326.91
1주일 범위
$266.93
$326.91
52주 변동 폭
$26.70
$326.91
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
317.25 | 8.26B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus - Insider Monkey
Aug PreEarnings: Can Praxis Precision Medicines Inc outperform in the next rallyPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom - TechStock²
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 7%Here's Why - MarketBeat
Praxis Precision Medicines (PRAX) Price Target Increased by 14.92% to 471.78 - Nasdaq
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - Quiver Quantitative
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.1%Here's Why - MarketBeat
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating | PRAX Stock News - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Two new brain disorder drugs head to FDA as Praxis nears key 2026 data - Stock Titan
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Insider Monkey
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biopharmaceutical company uses stock grants to attract three new employees - Stock Titan
How Praxis’s Big Equity Raise, Ulixacaltamide Breakthrough Status And Board Shake-Up At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Sahm
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines appoints new board members, promotes executives - Investing.com
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Chartmill
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
S P Trends: Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meetingJuly 2025 Selloffs & Real-Time Stock Movement Alerts - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
New leadership steps in as Praxis prepares for potential brain drug launches - Stock Titan
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
PRAX Stock Surge: Time to Buy? - StocksToTrade
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines Announces Major Underwritten Equity Offering - TipRanks
Praxis Precision Medicines Announces Underwritten Offering - TradingView — Track All Markets
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 8.2%What's Next? - MarketBeat
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
4.73%
0.92%
자본화:
|
볼륨(24시간):